Report Thumbnail
Product Code QY09135144883TW
Published Date 2024/6/10
QY Research
English167 PagesGlobal

Global Vaccine Adjuvants Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY09135144883TW◆The Jun 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/6/10
QY Research
English 167 PagesGlobal

Global Vaccine Adjuvants Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
The global Vaccine Adjuvants market is projected to reach US$ 1569.9 million by 2030 from an estimated US$ 936.1 million in 2024, at a CAGR of 9.0% during 2024 and 2030.
The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vaccine Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Vaccine Adjuvants.
The Vaccine Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vaccine Adjuvants market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vaccine Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios
Segment by Type
Aluminum Adjuvant
Emulsions Adjuvant
Others
Segment by Application
Human Vaccine
Veterinary Vaccine
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Vaccine Adjuvants in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine Adjuvants sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.

Table of Contents

  • 1 Study Coverage

    • 1.1 Vaccine Adjuvants Product Introduction
    • 1.2 Market by Type
      • 1.2.1 Global Vaccine Adjuvants Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
      • 1.2.2 Aluminum Adjuvant
      • 1.2.3 Emulsions Adjuvant
      • 1.2.4 Others
    • 1.3 Market by Application
      • 1.3.1 Global Vaccine Adjuvants Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
      • 1.3.2 Human Vaccine
      • 1.3.3 Veterinary Vaccine
    • 1.4 Study Objectives
    • 1.5 Years Considered

  • 2 Executive Summary

    • 2.1 Global Vaccine Adjuvants Market Size Estimates and Forecasts
      • 2.1.1 Global Vaccine Adjuvants Revenue 2019-2030
      • 2.1.2 Global Vaccine Adjuvants Sales 2019-2030
    • 2.2 Vaccine Adjuvants Market Size by Region: 2023 Versus 2030
    • 2.3 Vaccine Adjuvants Sales by Region (2019-2030)
      • 2.3.1 Global Vaccine Adjuvants Sales by Region: 2019-2024
      • 2.3.2 Global Vaccine Adjuvants Sales Forecast by Region (2025-2030)
      • 2.3.3 Global Vaccine Adjuvants Sales Market Share by Region (2019-2030)
    • 2.4 Vaccine Adjuvants Market Estimates and Projections by Region (2025-2030)
      • 2.4.1 Global Vaccine Adjuvants Revenue by Region: 2019-2024
      • 2.4.2 Global Vaccine Adjuvants Revenue Forecast by Region (2025-2030)
      • 2.4.3 Global Vaccine Adjuvants Revenue Market Share by Region (2019-2030)

  • 3 Global Vaccine Adjuvants by Manufacturers

    • 3.1 Global Top Vaccine Adjuvants Manufacturers by Sales
      • 3.1.1 Global Vaccine Adjuvants Sales by Manufacturer (2019-2024)
      • 3.1.2 Global Vaccine Adjuvants Sales Market Share by Manufacturer (2019-2024)
    • 3.2 Global Top Vaccine Adjuvants Manufacturers by Revenue
      • 3.2.1 Global Vaccine Adjuvants Revenue by Manufacturer (2019-2024)
      • 3.2.2 Global Vaccine Adjuvants Revenue Share by Manufacturer (2019-2024)
    • 3.3 Global Vaccine Adjuvants Price by Manufacturer (2019-2024)
    • 3.4 Competitive Landscape
      • 3.4.1 Key Vaccine Adjuvants Manufacturers Covered: Ranking by Revenue
      • 3.4.2 Global Vaccine Adjuvants Market Concentration Ratio (CR5 and HHI) & (2019-2024)
      • 3.4.3 Global Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.5 Global Vaccine Adjuvants Manufacturing Base Distribution, Product Type
      • 3.5.1 Vaccine Adjuvants Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.5.2 Manufacturers Vaccine Adjuvants Product Type
      • 3.5.3 Date of International Manufacturers Enter into Vaccine Adjuvants Market
    • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

  • 4 Company Profiles

    • 4.1 GSK
      • 4.1.1 GSK Company Information
      • 4.1.2 GSK Description, Business Overview
      • 4.1.3 GSK Vaccine Adjuvants Products Offered
      • 4.1.4 GSK Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.1.5 GSK Vaccine Adjuvants Sales by Product in 2023
      • 4.1.6 GSK Vaccine Adjuvants Sales by Application in 2023
      • 4.1.7 GSK Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.1.8 GSK Recent Developments
    • 4.2 CSL Limited
      • 4.2.1 CSL Limited Company Information
      • 4.2.2 CSL Limited Description, Business Overview
      • 4.2.3 CSL Limited Vaccine Adjuvants Products Offered
      • 4.2.4 CSL Limited Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.2.5 CSL Limited Vaccine Adjuvants Sales by Product in 2023
      • 4.2.6 CSL Limited Vaccine Adjuvants Sales by Application in 2023
      • 4.2.7 CSL Limited Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.2.8 CSL Limited Recent Developments
    • 4.3 Croda
      • 4.3.1 Croda Company Information
      • 4.3.2 Croda Description, Business Overview
      • 4.3.3 Croda Vaccine Adjuvants Products Offered
      • 4.3.4 Croda Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.3.5 Croda Vaccine Adjuvants Sales by Product in 2023
      • 4.3.6 Croda Vaccine Adjuvants Sales by Application in 2023
      • 4.3.7 Croda Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.3.8 Croda Recent Developments
    • 4.4 SEPPIC
      • 4.4.1 SEPPIC Company Information
      • 4.4.2 SEPPIC Description, Business Overview
      • 4.4.3 SEPPIC Vaccine Adjuvants Products Offered
      • 4.4.4 SEPPIC Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.4.5 SEPPIC Vaccine Adjuvants Sales by Product in 2023
      • 4.4.6 SEPPIC Vaccine Adjuvants Sales by Application in 2023
      • 4.4.7 SEPPIC Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.4.8 SEPPIC Recent Developments
    • 4.5 Novavax
      • 4.5.1 Novavax Company Information
      • 4.5.2 Novavax Description, Business Overview
      • 4.5.3 Novavax Vaccine Adjuvants Products Offered
      • 4.5.4 Novavax Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.5.5 Novavax Vaccine Adjuvants Sales by Product in 2023
      • 4.5.6 Novavax Vaccine Adjuvants Sales by Application in 2023
      • 4.5.7 Novavax Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.5.8 Novavax Recent Developments
    • 4.6 SPI Pharma
      • 4.6.1 SPI Pharma Company Information
      • 4.6.2 SPI Pharma Description, Business Overview
      • 4.6.3 SPI Pharma Vaccine Adjuvants Products Offered
      • 4.6.4 SPI Pharma Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.6.5 SPI Pharma Vaccine Adjuvants Sales by Product in 2023
      • 4.6.6 SPI Pharma Vaccine Adjuvants Sales by Application in 2023
      • 4.6.7 SPI Pharma Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.6.8 SPI Pharma Recent Development
    • 4.7 Phibro
      • 4.7.1 Phibro Company Information
      • 4.7.2 Phibro Description, Business Overview
      • 4.7.3 Phibro Vaccine Adjuvants Products Offered
      • 4.7.4 Phibro Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.7.5 Phibro Vaccine Adjuvants Sales by Product in 2023
      • 4.7.6 Phibro Vaccine Adjuvants Sales by Application in 2023
      • 4.7.7 Phibro Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.7.8 Phibro Recent Development
    • 4.8 SDA BIO
      • 4.8.1 SDA BIO Company Information
      • 4.8.2 SDA BIO Description, Business Overview
      • 4.8.3 SDA BIO Vaccine Adjuvants Products Offered
      • 4.8.4 SDA BIO Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.8.5 SDA BIO Vaccine Adjuvants Sales by Product in 2023
      • 4.8.6 SDA BIO Vaccine Adjuvants Sales by Application in 2023
      • 4.8.7 SDA BIO Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.8.8 SDA BIO Recent Development
    • 4.9 Invivogen
      • 4.9.1 Invivogen Company Information
      • 4.9.2 Invivogen Description, Business Overview
      • 4.9.3 Invivogen Vaccine Adjuvants Products Offered
      • 4.9.4 Invivogen Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.9.5 Invivogen Vaccine Adjuvants Sales by Product in 2023
      • 4.9.6 Invivogen Vaccine Adjuvants Sales by Application in 2023
      • 4.9.7 Invivogen Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.9.8 Invivogen Recent Development
    • 4.10 Tj Kaiwei
      • 4.10.1 Tj Kaiwei Company Information
      • 4.10.2 Tj Kaiwei Description, Business Overview
      • 4.10.3 Tj Kaiwei Vaccine Adjuvants Products Offered
      • 4.10.4 Tj Kaiwei Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.10.5 Tj Kaiwei Vaccine Adjuvants Sales by Product in 2023
      • 4.10.6 Tj Kaiwei Vaccine Adjuvants Sales by Application in 2023
      • 4.10.7 Tj Kaiwei Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.10.8 Tj Kaiwei Recent Development
    • 4.11 OZ Biosciences
      • 4.11.1 OZ Biosciences Company Information
      • 4.11.2 OZ Biosciences Description, Business Overview
      • 4.11.3 OZ Biosciences Vaccine Adjuvants Products Offered
      • 4.11.4 OZ Biosciences Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.11.5 OZ Biosciences Vaccine Adjuvants Sales by Product in 2023
      • 4.11.6 OZ Biosciences Vaccine Adjuvants Sales by Application in 2023
      • 4.11.7 OZ Biosciences Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.11.8 OZ Biosciences Recent Development
    • 4.12 Brenntag Biosector
      • 4.12.1 Brenntag Biosector Company Information
      • 4.12.2 Brenntag Biosector Description, Business Overview
      • 4.12.3 Brenntag Biosector Vaccine Adjuvants Products Offered
      • 4.12.4 Brenntag Biosector Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.12.5 Brenntag Biosector Vaccine Adjuvants Sales by Product in 2023
      • 4.12.6 Brenntag Biosector Vaccine Adjuvants Sales by Application in 2023
      • 4.12.7 Brenntag Biosector Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.12.8 Brenntag Biosector Recent Development
    • 4.13 MVP Laboratories
      • 4.13.1 MVP Laboratories Company Information
      • 4.13.2 MVP Laboratories Description, Business Overview
      • 4.13.3 MVP Laboratories Vaccine Adjuvants Products Offered
      • 4.13.4 MVP Laboratories Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.13.5 MVP Laboratories Vaccine Adjuvants Sales by Product in 2023
      • 4.13.6 MVP Laboratories Vaccine Adjuvants Sales by Application in 2023
      • 4.13.7 MVP Laboratories Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.13.8 MVP Laboratories Recent Development
    • 4.14 Zhuoyue
      • 4.14.1 Zhuoyue Company Information
      • 4.14.2 Zhuoyue Description, Business Overview
      • 4.14.3 Zhuoyue Vaccine Adjuvants Products Offered
      • 4.14.4 Zhuoyue Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.14.5 Zhuoyue Vaccine Adjuvants Sales by Product in 2023
      • 4.14.6 Zhuoyue Vaccine Adjuvants Sales by Application in 2023
      • 4.14.7 Zhuoyue Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.14.8 Zhuoyue Recent Development
    • 4.15 Aphios
      • 4.15.1 Aphios Company Information
      • 4.15.2 Aphios Description, Business Overview
      • 4.15.3 Aphios Vaccine Adjuvants Products Offered
      • 4.15.4 Aphios Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
      • 4.15.5 Aphios Vaccine Adjuvants Sales by Product in 2023
      • 4.15.6 Aphios Vaccine Adjuvants Sales by Application in 2023
      • 4.15.7 Aphios Vaccine Adjuvants Sales by Geographic Area in 2023
      • 4.15.8 Aphios Recent Development

  • 5 Breakdown Data by Type

    • 5.1 Global Vaccine Adjuvants Sales by Type (2019-2030)
      • 5.1.1 Global Vaccine Adjuvants Sales by Type (2019-2024)
      • 5.1.2 Global Vaccine Adjuvants Sales Forecast by Type (2025-2030)
      • 5.1.3 Global Vaccine Adjuvants Sales Market Share by Type (2019-2030)
    • 5.2 Global Vaccine Adjuvants Revenue Forecast by Type (2019-2030)
      • 5.2.1 Global Vaccine Adjuvants Revenue by Type (2019-2024)
      • 5.2.2 Global Vaccine Adjuvants Revenue Forecast by Type (2025-2030)
      • 5.2.3 Global Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
    • 5.3 Vaccine Adjuvants Average Selling Price (ASP) by Type (2019-2030)

  • 6 Breakdown Data by Application

    • 6.1 Global Vaccine Adjuvants Sales by Application (2019-2030)
      • 6.1.1 Global Vaccine Adjuvants Sales by Application (2019-2024)
      • 6.1.2 Global Vaccine Adjuvants Sales Forecast by Application (2025-2030)
      • 6.1.3 Global Vaccine Adjuvants Sales Market Share by Application (2019-2030)
    • 6.2 Global Vaccine Adjuvants Revenue Forecast by Application (2019-2030)
      • 6.2.1 Global Vaccine Adjuvants Revenue by Application (2019-2024)
      • 6.2.2 Global Vaccine Adjuvants Revenue Forecast by Application (2025-2030)
      • 6.2.3 Global Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
    • 6.3 Vaccine Adjuvants Average Selling Price (ASP) by Application (2019-2030)

  • 7 North America

    • 7.1 North America Vaccine Adjuvants Market Size YoY Growth 2019-2030
    • 7.2 North America Vaccine Adjuvants Market Facts & Figures by Country
      • 7.2.1 North America Vaccine Adjuvants Sales by Country (2019-2030)
      • 7.2.2 North America Vaccine Adjuvants Revenue by Country (2019-2030)
    • 7.3 North America Vaccine Adjuvants Sales by Type (2019-2024)
    • 7.4 North America Vaccine Adjuvants Sales by Application (2019-2024)

  • 8 Asia-Pacific

    • 8.1 Asia-Pacific Vaccine Adjuvants Market Size YoY Growth 2019-2030
    • 8.2 Asia-Pacific Vaccine Adjuvants Market Facts & Figures by Region
      • 8.2.1 Asia-Pacific Vaccine Adjuvants Sales by Region (2019-2030)
      • 8.2.2 Asia-Pacific Vaccine Adjuvants Revenue by Region (2019-2030)
    • 8.3 Asia-Pacific Vaccine Adjuvants Sales by Type (2019-2024)
    • 8.4 Asia-Pacific Vaccine Adjuvants Sales by Application (2019-2024)

  • 9 Europe

    • 9.1 Europe Vaccine Adjuvants Market Size YoY Growth 2019-2030
    • 9.2 Europe Vaccine Adjuvants Market Facts & Figures by Country
      • 9.2.1 Europe Vaccine Adjuvants Sales by Country (2019-2030)
      • 9.2.2 Europe Vaccine Adjuvants Revenue by Country (2019-2030)
    • 9.3 Europe Vaccine Adjuvants Sales by Type (2019-2024)
    • 9.4 Europe Vaccine Adjuvants Sales by Application (2019-2024)

  • 10 Latin America

    • 10.1 Latin America Vaccine Adjuvants Market Size YoY Growth 2019-2030
    • 10.2 Latin America Vaccine Adjuvants Market Facts & Figures by Country
      • 10.2.1 Latin America Vaccine Adjuvants Sales by Country (2019-2030)
      • 10.2.2 Latin America Vaccine Adjuvants Revenue by Country (2019-2030)
    • 10.3 Latin America Vaccine Adjuvants Sales by Type (2019-2024)
    • 10.4 Latin America Vaccine Adjuvants Sales by Application (2019-2024)

  • 11 Middle East and Africa

    • 11.1 Middle East and Africa Vaccine Adjuvants Market Size YoY Growth 2019-2030
    • 11.2 Middle East and Africa Vaccine Adjuvants Market Facts & Figures by Country
      • 11.2.1 Middle East and Africa Vaccine Adjuvants Sales by Country (2019-2030)
      • 11.2.2 Middle East and Africa Vaccine Adjuvants Revenue by Country (2019-2030)
    • 11.3 Middle East and Africa Vaccine Adjuvants Sales by Type (2019-2024)
    • 11.4 Middle East and Africa Vaccine Adjuvants Sales by Application (2019-2024)

  • 12 Supply Chain and Sales Channel Analysis

    • 12.1 Vaccine Adjuvants Supply Chain Analysis
    • 12.2 Vaccine Adjuvants Key Raw Materials and Upstream Suppliers
    • 12.3 Vaccine Adjuvants Clients Analysis
    • 12.4 Vaccine Adjuvants Sales Channel and Sales Model Analysis
      • 12.4.1 Vaccine Adjuvants Distribution Channel Analysis: Indirect Sales VS Direct Sales
      • 12.4.2 Vaccine Adjuvants Distribution Channel Analysis: Online Sales VS Offline Sales
      • 12.4.3 Vaccine Adjuvants Distributors

  • 13 Market Dynamics

    • 13.1 Vaccine Adjuvants Industry Trends
    • 13.2 Vaccine Adjuvants Market Drivers
    • 13.3 Vaccine Adjuvants Market Challenges
    • 13.4 Vaccine Adjuvants Market Restraints

  • 14 Research Findings and Conclusion

  • 15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details
    • 15.3 Disclaimer
USD 5,900 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.